TO THE EDITOR
Waldenstrom macroglobulinemia (WM) is a clinical syndrome characterized by a serum IgM paraprotein and a lymphoplasmacytic bone marrow infiltrate.
1 Patient may present with organomegaly, anemia, hyperviscosity, cryoglobulinemia, amyloidosis and autoimmune disease. While WM has clinical and pathological features resembling multiple myeloma (MM) or chronic lymphocytic leukemia (CLL), little is known about its pathogenesis. We and others have recently shown that translocations involving immunoglobulin heavy-chain gene (IgH) and deletions of chromosome 13q14 are the most common and prognostic significant genetic changes in MM with a frequency up to 75 and 50%, respectively.
2-4 Deletions of 13q14 are also the most frequent genomic aberration in CLL with a frequency of 55%. 5 Deletions of the p53 tumor suppressor gene at locus 17p13.1 are found in 7% of patients with CLL 5 and 10% of patients with MM. 3 As the data on these molecular cytogenetic changes in WM are limited, we used cytoplasmic IgM fluorescence combined with interphase fluorescence in situ hybridization (cIg-FISH) to evaluate these genomic aberrations in 22 patients with WM.
WM was diagnosed if the patient had an IgM monoclonal protein of 5 g/l or greater and a clonal bone marrow lymphoplasmacytic infiltrate. In all, 22 patients met the diagnostic criteria for WM and were entered on study. The clinical and laboratory features are shown in Table 1 . Of 22 cases, 12 were males and 10 females. The median age was 62 years. Of the patients, 77% had kappa light chains. The bone marrow aspirate samples were obtained at diagnosis in nine patients and later in the disease in 13 patients. Flow cytometric immunophenotyping was performed in 15 cases and detected moderate to bright immunofluorescence of pan B-cell markers CD19 and CD20 in all cases. CD5 was expressed in two cases (13%) and CD10 in one (7%). CD23 was positive in 40% of the cases and FMC7 in 60%. Light-chain expression was bright in all the cases tested. The median percentage of bone marrow lymphoplasmacytic cells was 50%. Karyotypes were available in four cases, which were all normal.
Bone marrow samples were obtained at the time of active disease. Mononuclear cells were enriched using a Ficoll-gradient centrifugation method. Cytoplasmic Ig-FISH was performed as described previously. 4 The FISH results are shown in Table 2 . The representative images are shown in Figure 1 . Interphase cIg-FISH detected an IgH break-apart signal pattern indicating an IgH translocation in three cases (14%). The percentage of clonal cells with IgH translocations ranged from 23 to 34%. We used specific dual color probes for IgH translocation partners: t(11;14) involving cyclin D1, t(4;14) involving FGFR3, t(14;16) involving c-maf and t(8;14) involving c-myc. None of these translocation partners were detected in these three cases.
Loss of one 13q14 signal was detected in two cases (9%) indicative of a hemizygous 13q14 deletion. The percentages of clonal cells with 13q14 deletions were 36 and 73% in these two cases. Hemizygous deletions of 17p13.1(p53) were found in two cases (9%). In both cases, the most common pattern was an interstitial deletion with the loss of one 17p13.1(p53) signal and two remaining CEP17 probe signals. The percentages of clonal IgH translocations are frequent in B-cell malignancies, but rarely seen in WM. Using a cytoplasmic interphase FISH V H /C H break-apart strategy, Schop et al 6 recently found one of 31 patients (3%) with WM harbored IgH translocations in 37% of clonal cells. In our study, we found three of 22 cases (14%) had IgH translocations involving 23-34% of the clonal cells analyzed. The data indicate that IgH translocations occur in patients with WM, but are much less frequent and involve fewer clonal cells than patients with MM. The data also suggest that IgH translocations may not be the initiating events for the pathogenesis of WM in contrast to MM and some B-cell lymphomas. 7 We found deletions of 13q14 or 17p13.1(p53) in 9% of the cases. Previous report by Schop et al 8 also found infrequent deletions of these two regions (B15%) in WM, and noted that patients with deletions were more likely to be later in the course of the disease. In our series, the samples with 13q14 or 17p13.1 deletions were all obtained later in the course of the disease. Unlike Schop et al, we did not find that patients with 17p13.1(p53) deletions had a higher percentage involvement of clonal cells in the bone marrow in comparison to patients who had 13q14 deletions. Deletions of 13q14 or 17p13.1(p53) are associated with poor prognosis in patients with MM, 3 whereas deletions of 13q14 confer a good prognosis in patients with CLL. 5 The prognostic significance of these deletions in WM can only be addressed in a larger prospective study.
In conclusion, our data indicate that IgH translocations, 13q14 and 17p13.1(p53) deletions, are present but uncommon in patients with WM. The molecular cytogenetic abnormalities suggest that WM is different from MM, in which IgH translocations and 13q deletions are frequently detected and may represent primary genetic events in the pathogenesis of myeloma. WM also differs from CLL that has much frequent 13q14 deletions. The primary or secondary genetic events in the pathogenesis of WM remain unknown. One recent study revealed high prevalence of chromosome 6q deletions in WM by FISH. 6 Further identification of potential tumor suppressor gene(s) in the minimal deleted region on chromosome 6q may shed light on pathogenesis of WM. Examples of normal and abnormal hybridization patterns for IgH (a), 13q14(b) and 17p13.1(p53) (c) probes. To study IgH translocations, we used a break-apart strategy, using a V H probe (labeled green) specific for the IgH variable region and a C H probe (labeled red) specific for the IgH constant region (LSI IgH dual color (14q32), Vysis). Break apart of probe signals (segregation) was defined by a distance of more than three signal widths between two differentially labeled probe signals (a). To detect p53 deletions, we used a 17p13.1 probe labeled in SpectrumRed (LSI p53, Vysis) and a chromosome 17 alpha-satellite-DNA centromere probe labeled in SpectrumGreen (CEP17, Vysis). A normal pattern was considered to be a pair of red and green signals (2R2G). A deletion of 13q14 was observed when there was a loss of one of the red signals (1R2G) (b). An abnormal pattern for p53 deletion was loss of signal(s) from one of the pair probes (1R2G, 1R1G) (c). Patients were considered evaluable if at least 100 clonal cells (stained positive for cytoplasmic IgM) could be scored from each slide. The background cutoff level was 10% for all the probe sets. 1 Although part of the familial clustering observed is likely to be mediated through inherited factors a robust model of disease inheritance has not been established and to date no gene, which when mutated in the germline, has been shown to confer susceptibility to the disease.
1 It is probable that disease susceptibility is mediated in part by both genetic and nongenetic factors.
A number of diseases are well documented to show excess sex concordance of affected sibling pairs, whereby there are more non-twin, affected male-male and female-female sibling pairs and fewer mixed-sex pairs than would be expected by chance alone.
2 Such data provide information on the relative contribution of nongenetic factors to familial clustering.
We have previously noted an excess sex concordance in sibpairs with CLL.
3 This observation was based primarily on data accessed from published case reports. It is possible, however, that a reporting bias in favour of same sex cases within CLL families may exist in the literature so favouring the appearance of sex concordance with the disease. To address this issue we have analysed a larger series of CLL families randomly ascertained through a CLL linkage consortium.
Families with two or more individuals affected with CLL were ascertained through haematologists in Australia, the United Kingdom, Norway, Israel, Italy, Germany, Portugal and Poland. Information on family history of cancer was obtained by use of a previously validated standard questionnaire administered to index patients personally or by phone after reviewing informed consent. Index patients provided information on dead and noncontactable members of their families. These data were confirmed as carefully as possible by reviewing medical records. Criteria for inclusion in this analysis required that both siblings had identical biological parents and that CLL had been diagnosed on the basis of recognised haematological and immunological criteria. Twins and families that had more than two siblings affected with CLL were excluded from the analysis. The study was undertaken with informed consent and ethical review board approval in strict accordance with the tenets of the Helsinki declaration.
Sibling pairs were classified as male-male, male-female, or female-female. Expected numbers of pairs in each category were computed assuming a random distribution with the frequency of male-male (MM) pairs defined by np 2 ; male-female (MF) defined by 2npq, and female-female (FF) defined by nq 2 , where p and q represent the proportions of males and females respectively, and n the total number of sibling pairs observed. The probabilities of a sibling being male or female were computed from the total population of affected sibling pairs. Sex concordance was calculated by using the w 2 -test statistic with 1 df to test for differences between observed and expected numbers of pairs. Statistical computations were undertaken using the program STATA (version 7, Stata Corporation) making use of the GENHWI module.
In total, 122 sibling pairs affected with CLL were analysed. As with sporadic disease the overall prevalence of CLL was greater for males than for females, 0.62 and 0.38 respectively. A striking excess of both MM and FF pairs observed. The sex distribution was 55 MM (expected 46.7), 41 MF (expected 57.6), and 26 FF (expected 17.7) pairs. The distribution of pairs was, therefore, statistically significant from those expected (P ¼ 0.0015). The relative risk for sibling sex concordance, defined by the observed ratio of concordant/discordant sibling pairs divided by the expected concordant/discordant ratio, was 1.8.
In this study we have sought to avoid possible ascertainment bias that may be present in our previous report 3 by analysing families collected for genetic linkage analysis with no selection for sex. Although CLL is more common among males this will not account for the distortion in sex concordance observed since the expected frequencies were calculated on the basis of the overall prevalence of male and female cases in the sample set.
The excess sex concordance seen in familial CLL is difficult to explain by a simple genetic model. A similar segregation pattern has been documented in Hodgkin's disease, suggesting the disease is pseudo-autosomally (PAR) linked. 4 The X-and Ychromosomes share two homologous pseudoautosomal regions that recombine at meiosis -PAR1 and PAR2 at the tips of the short arms and long arms, respectively. PAR genes exhibit a unique segregation pattern with affected sibs tending to be of the same sex. Cases of Hodgkin's disease are seen in families segregating CLL and both diseases have a common clonal origin, 1 suggesting PAR genes may contribute to B-cell tumour occurrence. Sex concordance may alternatively be a consequence of shared environment as it is more probable that within any family, a sister pair or brother pair are more likely to share a common environment than unlike-sex siblings. Such a notion would correlate with environmental disease triggers such as viral exposure being a risk factor for Hodgkin's lymphoma. 5 It is intriguing that the diseases displaying sex concordance reported to date are all typified by immunological dysfunction and show a strong HLA association -Behcets, sarcoidosis, multiple sclerosis and Hodgkin's disease 6 suggesting that if environmental exposure is a risk factor it is operating on a background of inherited susceptibility. The notion that HLA may also contribute to CLL susceptibility is supported by recent work.
7 Furthermore, preferred usage of specific IG gene segments has been reported in three sisters affected with CLL. 
